ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

ESMO Guidelines Committee

doi:10.1016/j.annonc.2024.03.001

ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

ESMO Guidelines Committee

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

10 Citations (Scopus)

langue originale	Anglais
Pages (de - à)	485-490
Nombre de pages	6
journal	Annals of Oncology
Volume	35
Numéro de publication	6
Les DOIs	https://doi.org/10.1016/j.annonc.2024.03.001
état	Publié - 1 juin 2024
Modification externe	Oui

Accès au document

10.1016/j.annonc.2024.03.001

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{ec0a53d0b5dc4344af1d197de03c67c0,

title = "ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma",

keywords = "bladder cancer, enfortumab vedotin, fibroblast growth factor receptor inhibitor, nivolumab, pembrolizumab, urothelial carcinoma",

author = "{ESMO Guidelines Committee} and T. Powles and J. Bellmunt and E. Comperat and {De Santis}, M. and R. Huddart and Y. Loriot and A. Necchi and Valderrama, {B. P.} and A. Ravaud and Shariat, {S. F.} and B. Szabados and {van der Heijden}, {M. S.} and S. Gillessen",

year = "2024",

month = jun,

day = "1",

doi = "10.1016/j.annonc.2024.03.001",

language = "English",

volume = "35",

pages = "485--490",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "6",

}

TY - JOUR

T1 - ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma

AU - ESMO Guidelines Committee

AU - Powles, T.

AU - Bellmunt, J.

AU - Comperat, E.

AU - De Santis, M.

AU - Huddart, R.

AU - Loriot, Y.

AU - Necchi, A.

AU - Valderrama, B. P.

AU - Ravaud, A.

AU - Shariat, S. F.

AU - Szabados, B.

AU - van der Heijden, M. S.

AU - Gillessen, S.

PY - 2024/6/1

Y1 - 2024/6/1

KW - bladder cancer

KW - enfortumab vedotin

KW - fibroblast growth factor receptor inhibitor

KW - nivolumab

KW - pembrolizumab

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85191616867&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2024.03.001

DO - 10.1016/j.annonc.2024.03.001

M3 - Article

C2 - 38490358

AN - SCOPUS:85191616867

SN - 0923-7534

VL - 35

SP - 485

EP - 490

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -